Cryoport, Inc. and VGXI, Inc., announced a strategic partnership to support biopharmaceutical companies in developing cell and gene therapies and mRNA-based treatments.
VGXI is a leading contract developer and manufacturer specializing in nucleic acid biopharmaceuticals, including gene therapies, DNA vaccines and RNA medicines, and ADC applications. Through this new partnership, Cryoport Systems will provide biostorage and bioservices from its Houston, Texas, facility for plasmid DNA products manufactured at VGXI's state-of-the-art facilities in The Woodlands, Texas, and its new headquarters and manufacturing location in Conroe, Texas. The collaboration brings together VGXI's industry-leading expertise in plasmid DNA manufacturing with Cryoport's fully integrated, end-to-end supply chain solutions. These include shipping services, data solutions and comprehensive support services, ensuring seamless final delivery to VGXI's end customers. Partnership operations are set to commence in October 2024.
Jerrell Shelton, CEO of Cryoport, commented, "Being chosen by VGXI as a partner for biostorage and bioservices underscores our shared commitment to quality and innovation. VGXI has a proven track record of delivering high-quality plasmid DNA for commercial gene therapies and clinical trial testing of leading treatment candidates. Together, we will provide biopharmaceutical companies a comprehensive and integrated solution to support clinical programs that are developing lifesaving, next-generation therapeutic modalities, a key part of our mission."
Young Park, CEO of VGXI, added, "We are thrilled to launch this partnership to support our client's advanced therapy programs, including cell and gene therapies, mRNA-based treatments and DNA vaccines. Choosing Cryoport as our trusted and reliable partner further elevates our mission by ensuring safe, secure, and world-class storage and transport of these assets."